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Abstract
Background: Maternal prenatal health has been shown to be an important influence on children’s developmental
outcomes, which has led to an increased emphasis on providing more information to support clinical decisions in
pregnancy. Several systematic reviews suggest that analgesic drug use during pregnancy may have neurodisruptive
properties. However, no firm conclusions have yet been drawn on the associations between prenatal analgesic
drug use and children’s long-term development of neurodevelopmental disorders such as autism spectrum
disorder (ASD) or attention deficit hyperactivity disorder (ADHD). Therefore, an umbrella review is proposed for the
purpose of examining the associations between maternal analgesic drug use during pregnancy and diagnoses of
neurodevelopmental disorders.
Methods: Included systematic reviews will consist of studies examining the effect of maternal prenatal analgesic
drug use, specifically ibuprofen, acetaminophen, aspirin, naproxen, diclofenac, and ketoprofen, on children’s
neurodevelopmental disorder status. Examined drugs were restricted to those readily accessible and frequently
used by pregnant women, and with characteristics that allow them to cross the placenta and directly affect fetal
development. Outcomes will be restricted to formal clinical diagnoses of ASD and/or ADHD. Two reviewers will
independently identify eligible reviews from six databases (e.g., PubMed, EMBASE, PsychINFO) from inception dates
of databases to the date of data extraction, and conduct manual searches of reference lists, consultation with field
experts, and scan of pre-print archives. Extracted data will also include short qualitative summaries by both
reviewers. As part of quality assessment, a standardized measurement tool to assess systematic reviews (AMSTAR 2)
will be used. A narrative synthesis is proposed to integrate findings from different, potentially methodologically
heterogeneous, studies.
Discussion: This umbrella review of associations between maternal prenatal use of analgesic drugs and children’s
neurodevelopmental disorders could allow for firmer conclusions to be drawn through the synthesis of all relevant
published research. The synthesis of findings using high-quality evidence could provide more accurate healthcare
information on the long-term effects of analgesic drugs on neurodevelopment, to better guide future clinical
decisions during pregnancy. This review will also allow gaps and methodological differences in the literature to be
identified, informing recommendations for future research.
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Background
Recent years have shown an increased emphasis on the
effects of maternal prenatal health on children’s long-
term development. Decisions made during pregnancy
should be as well-informed as possible to understand
possible long-term effects, such as on children’s neuro-
development. Since 1990, there has been global in-
creased awareness of neurodevelopmental disorders such
as autism spectrum disorder (ASD) and attention deficit
hyperactivity disorder (ADHD), with the worldwide
prevalence of ASD being 0.17–0.62% [1] and 5.29–7.20%
for ADHD [2, 3]. Currently, 56% of pregnant women are
reported to use analgesic drugs [4]. With this prevalence
rate, it is worthwhile to examine the effects of prenatal
drug use on a child’s long-term development.
With increased cardiac output and blood flow that oc-
curs as part of the physiological changes during preg-
nancy, drug absorption also increases [5]. This
bioavailability creates complex chemical changes in both
the mother and fetus. Studies on pharmacokinetic
changes in pregnancy show how placenta transfer occurs
between maternal and fetal blood circulatory systems
[6]. Some pharmacological characteristics of drugs that
cross the placenta include soluble lipids, unbound drugs
that are lower of degree of ionization and have a mo-
lecular weight of less than 500 g/mol [7]. Drugs that fall
under this category include aspirin, ibuprofen, naproxen,
and acetaminophen (paracetamol). With hormonal
changes in pregnancy and increased lipid levels dimin-
ishing the binding capacity of drugs [8], a fetus may ex-
perience large concentrations of drug doses, directly
affecting the developing brain.
Some medications of interest in this review, such as
acetaminophen and naproxen, are also antipyretic
drugs. Antipyretic drugs are prostaglandin antagonists
which affect the hypothalamus and decrease body
temperatures during an episode of fever. Untreated
fever in pregnancy has been associated with malfor-
mations in children, particularly neural tube defects,
heart defects, and oral clefts [9]. While there is some
evidence that antipyretic medication has a protective
effect, some pregnant women may use these medica-
tions without considering potential long-term effects
on their child’s development neurodevelopment [9].
As some women avoid mild analgesics/antipyretics
during pregnancy [10], women therefore need to care-
fully weigh the risks of untreated fever against the
risk of using mild analgesics/antipyretics.
During pregnancy, drugs may be used for a wide var-
iety of reasons, such as to alleviate pain, improve health,
or increase well-being. While previous research has sug-
gested neurodisruptive properties of certain drugs on
the fetus [11], some of these drugs are still not recog-
nized as human teratogens and are readily accessible to
the public. Current studies show that prenatal use of
drugs is frequent in pregnant women, with around 90%
of them taking some form of medication during preg-
nancy [12]. With analgesic drugs recorded as the most
commonly recommended class of drugs to be used dur-
ing pregnancy, it is possible that pregnant women are
engaging in this type of drug use without being aware of
potential long-term effects on their child.
Recognizing that there was insufficient information to
guide clinical decisions, the US Food and Drug Adminis-
tration (FDA) established new pregnancy exposure regis-
tries in 2002 in order to encourage the use of
prospective studies to obtain relevant data [13]. This
registry is similar to those in other countries, such as the
Swedish Medical Birth Register, which was established
in 1973, and has collected information on drugs used
during pregnancy since 1995 [14]. However, at the time
of writing, neither of these registers have produced re-
search with firm conclusions regarding prenatal expos-
ure to analgesic drugs and their influence on children’s
neurodevelopmental outcomes.
Since January 2016, the FDA also proposed changing
medication labels in order to provide more information
for pregnant women. Despite having shown that anal-
gesic drugs cross the placenta, most of them have been
placed under either FDA categories:
category B:
“Animal reproduction studies have failed to demon-
strate a risk to the fetus and there are no adequate and
well-controlled studies in pregnant women, or animal
studies have shown adverse effects, but adequate and
well-controlled studies in pregnant women have failed to
demonstrate a risk to the fetus in any trimester,”
or category C:
“Animal reproduction studies have shown an adverse
effect on the fetus and there are no adequate and well-
controlled studies in humans, but potential benefits may
warrant use of the drug in pregnant women despite po-
tential risks,”
or category D:
“There is positive evidence of human fetal risk, but the
benefits from use in pregnant women may be acceptable
Kwok et al. Systematic Reviews           (2020) 9:202 Page 2 of 7
despite the risk (e.g., if the drug is needed in a life-
threatening situation or for a serious disease in which
safer drugs cannot be used or are ineffective)” [15, 16].
This illustrates that current clinical guidelines are still
based on limited and inconsistent evidence regarding the
long-term effects of these drugs on the fetus.
Research has suggested that prenatal drug use is asso-
ciated with increased behavioral symptoms such as con-
duct problems and hyperactivity at age 7 [17]. Further, a
systematic review of nine studies suggested that prenatal
exposure to analgesic drugs such as acetaminophen was
associated with an increased risk of neurodevelopmental
disorders between 18 months and 3 years [18]. These re-
sults are consistent with another systematic review of
seven retrospective cohort studies [11] that found a sig-
nificantly increased risk of ASD and ADHD in children
with age ranges of 3 to 12 years old, in relation to pre-
natal acetaminophen use. However, other reviews ques-
tion conclusions on links between prenatal analgesic
drug use and neurodevelopmental disorders in children
and suggest that findings may be influenced by unmeas-
ured confounding [19, 20]. The above studies and na-
tional registries imply that current research or
government initiatives are not yet sufficient in nature to
understand long-term effects of prenatal analgesic drug
use on a child’s development. Thus, an umbrella review
is needed to provide a comprehensive overview of the
existing evidence in this field.
Systematic reviews have long been held as the gold-
standard in contributing to evidence-based healthcare by
informing decision-making processes [21]. The next step
in conducting an umbrella review offers valuable insight
through providing an overall summary of multiple sys-
tematic reviews; effectively synthesizing, comparing, and
contrasting results of published systematic reviews and
meta-analyses. Umbrella reviews are conducted in line
with the same principles as systematic reviews, in terms
of, for example, predefined search strategies, quality
assessment, and reporting guidelines. However, the sub-
ject of an umbrella review is existing systematic reviews
and meta-analyses, rather than original research studies
[21, 22]. The objectives the proposed umbrella review
also align with Cochrane’s overview of reviews, consist-
ing of (1) a clearly formulated objective to answer a spe-
cific research question, (2) inclusion of only systematic
reviews, (3) explicit and reproducible methods of identi-
fication and risk/quality assessment, (4) collection and
presentation of data from studies (description of system-
atic reviews, risk of bias, quantitative outcome data, cer-
tainty of evidence using a clinical outcome framework
such as GRADE assessments), and (5) discussion of find-
ings related to specific research questions (i.e., summary
of main results, completeness, applicability and quality
of evidence, agreements, and/or disagreements with
other studies) [23]. The topic of associations between
maternal prenatal use of analgesic drugs and children’s
neurodevelopmental disorders has reached a level of ma-
turity where it can benefit from this form of synthesis,
further allowing for firmer conclusions to be drawn
through an overall examination of published research.
The aims of the proposed umbrella review are to (a)
summarize and synthesize findings from systematic re-
views or meta-analyses on links between analgesic drug
use in pregnancy and children’s diagnoses of neurodeve-
lopmental disorders, specifically ASD and ADHD; (b)
use high-quality evidence to provide firm conclusions
from current literature, in order to inform healthcare
guidance for pregnant women; and (c) identify gaps and
methodological weaknesses in the literature to inform
recommendations for future research in this area.
Methods
Registration and reporting information
The umbrella review protocol is being reported in ac-
cordance with the reporting guidance provided in the
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses Protocols (PRISMA-P) statement [24]
(Additional File 5). This protocol has been registered
within the International Prospective Register of System-
atic Reviews (PROSPERO) database (registration ID:
CRD42040179216).
Inclusion criteria
Included studies will be based on the following eligibility
criteria:
Population
Study populations will include pregnant women and the
children resulting from their pregnancies. No age limit is
set for the pregnant women nor their offspring.
Exposures
Only systematic reviews or meta-analyses examining the
effects of analgesic drugs will be included in this review.
Drugs reviewed will fulfill the criteria of easy access and
common usage [25] and have characteristics that allow
them to cross the placenta and directly affect the devel-
opment of the fetus [6]. This umbrella review will focus
on reviews of the following specific medications: ibupro-
fen, acetaminophen, aspirin, naproxen, diclofenac, and
ketoprofen. ASD and ADHD assessed by any means
(e.g., clinical diagnoses, parent- or teacher-report) [11]
will be included in this review. All types of autism
spectrum disorders (e.g., pervasive developmental dis-
order (not otherwise specified) and Asperger’s disorder)
will be included in this review. All types of attention def-
icit hyperactivity disorders (e.g., attention deficit
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disorders, hyperkinetic disorders) will be included in this
review.
Setting
Healthcare settings will include both hospital and com-
munity data. The study will cover the analgesic drugs
taken during the period of pregnancy only.
Outcomes
All reviews which draw on indications of ASD, ADHD,
or co-occurring ASD and ADHD, assessed by any
means, as outcomes will be included, as will gender-
specific reviews. No upper age limit restrictions will be
applied for study outcomes.
Study design
Only reviews of studies which include human offspring
will be considered for this review. Only reviews of quan-
titative studies will be included. The review will be re-
stricted to systematic reviews and meta-analyses but will
not be restricted to reviews of studies of a particular de-
sign (e.g., longitudinal or cross-sectional). Methodo-
logical differences will be discussed in the umbrella
review.
Language
Limits will be set to only meta-analysis and systematic
reviews in the English language due to the language cap-
abilities of the study team.
Exclusion criteria
Excluded studies will be based on the following criteria:
Population
Studies on non-human mammals only will be excluded.
Exposures
Reviews focusing on non-analgesic drugs or illegal drugs
will not be included in this review, neither will studies
examining neurodevelopmental disorders other than
ASD or ADHD.
Study design
Articles that are not relevant to the review’s scope of
prenatal use of analgesic drugs or children’s ASD or
ADHD will be excluded. Types of articles which will be
excluded are primary or original research, non-
systematic reviews (e.g., narrative or scoping reviews),
case studies or qualitative reviews, and reviews that draw
on published opinion or theoretical studies as a primary
source of evidence.
Two reviewers will assess studies against the inclusion
and exclusion criteria.
Search strategy
A search will be performed through major repositories
of systematic reviews and meta-analyses, namely the fol-
lowing databases: Embase, Maternity and Infant Care,
PsycINFO, PsycARTICLES, PubMed, and Cochrane Li-
brary. Boolean operators of “AND” and “OR” will be
used for search terms and adapted for different data-
bases. Search filters will be employed and presented se-
quentially for the databases with key terms searched for
in the title or abstract fields. Relevant subject headings
will also be used in addition to keywords (e.g., “Prenatal
exposure drugs neurodevelopment” in the EMTREE the-
saurus, or “Prenatal drugs effect ASD” in the MeSH
thesaurus).
A list of example search terms is included in Add-
itional File 3. Search periods will extend from the incep-
tion dates of the databases to the date of data extraction.
The reference manager Zotero will be used to store re-
cords and identify duplicates.
In order to provide a comprehensive search, reference
lists of selected reviews, reviews in-press (derived from
scanning pre-print archives or discussion with field ex-
perts), will form part of the supplementary search strat-
egy and recorded under “additional records.” These
include contacting study authors, manual searches of
gray literature (such as Open Grey, Virtual Health Li-
brary), and preprint platforms (such as arXiv.org, medR-
xiv.org, PsyArXiv.com, Open Science Framework [OSF]
preprints).
Screening and selection procedure
Data extraction
Data extraction and coding will be independently carried
out by two researchers. All articles identified from the
literature search will be independently screened by two
researchers. First, titles and abstracts of articles will be
screened based on the eligibility criteria as outlined
above. Second, full texts will be examined in detail and
screened for eligibility. Third, references of all consid-
ered articles will be searched manually to identify any
relevant reports that may have been missed in the initial
search strategy. Any disagreements will be resolved
through discussion by the researchers to meet a consen-
sus, if necessary. Information extracted from each study
will include first author, year of publication, reported a
protocol, objective(s), reported strategies to search litera-
ture, number of databases searched and date of last
search, inclusion/exclusion criteria, population, main
outcomes of interest, type of study designs included
(e.g., observational studies), number of included studies,
number of studies reporting data for meta-analyses, ef-
fect metric(s) reported (e.g., risk ratio), methods to as-
sess study risk of bias, additional analyses, metabias
assessment (e.g., publication bias across studies), funding
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source, and conflicts of interest. Extracted data will be
stored in spreadsheets which will be used to determine
eligibility for inclusion in the umbrella review.
Any discrepancies will be solved through discussion
until consensus is achieved, with the assistance of the
third researcher if needed. Studies with missing essential
information such as participant data or search strategies
will not be included in the final review. A PRISMA flow
diagram showing the number of studies included and ex-
cluded at each stage of the study selection process will
be provided [24] (Additional File 4). The umbrella re-
view will undergo a full pilot process using a small sam-
ple of papers before a full review is initiated.
Quality assessment
A proposed quality assessment, the AMSTAR 2 (A
MeaSurement Tool to Assess systematic Reviews-2)
[26] will be used for this umbrella review (Additional
File 2). This updated version of a critical appraisal
tool was chosen for rapid quality assessments of sys-
tematic reviews in healthcare. The AMSTAR 2 tool
consists of 16-items addressing search strategies, data
extraction techniques, bias risk, appropriate method-
ology, and interpretation and discussion of results.
Seven domains within the AMSTAR 2 are regarded
as “critical” and flaws in these domains are deemed
to affect the validity of the review (assessed by items
2, 4, 7, 9, 11, 13, 15). The AMSTAR 2 authors
propose a scoring scheme which categorizes the con-
fidence in the results of each review into “High,”
“Moderate,” “Low,” and “Critically low.” We will use
this scheme and reviews which we rate as “Critically
low” (the study has more than one critical flaw) will
be excluded from the data synthesis. Studies which
we deem “Low” (one critical flaw) will be included,
but their conclusions are given less weight.
The AMSTAR 2 not only allows for future replicabil-
ity, but also provides reviewers with little epidemio-
logical training with a standardized template, in order
for a more in-depth appraisal of the literature. It consists
of detailed questions. This tool is in line with advised
guidelines on the assessment of systematic reviews based
on identifying methodological features such as how well
the research question is defined, use of a systematic
search strategy, possible publication or funding bias, se-
lective reporting, previous quality ratings, and presence
of information synthesis and conclusion [27]. The
AMSTAR 2 will be modified to suit the topic for this
umbrella review through reducing the emphasis of ran-
domized control trials in the quality assessment process.
Data synthesis
A narrative synthesis method is proposed for this um-
brella review. Included studies will be tabulated with
an overall summary. We will provide a narrative syn-
thesis of the findings from each review, supported by
a table showing the results of the critical appraisal
based on included studies (as assessed by the modi-
fied AMSTAR 2 approach). The table will include a
description of key features, findings, variations of re-
search, and supplemented with graphics if relevant. A
meta-analysis will not be performed. This method was
primarily chosen due to the lack of firm conclusions
on prenatal analgesic drug use and potential hetero-
geneity of data from multiple systematic reviews and
meta-analyses. A narrative synthesis provides flexibil-
ity due to its qualitative rather than quantitative na-
ture of the analysis. The purpose of this narrative
synthesis is to examine and integrate ideas from mul-
tiple different reviews in order to provide a clear
overview of the effects of analgesic drugs on neurode-
velopmental diagnoses. Variations or discrepancies in
findings will be explored by comparing methodo-
logical features between reviews (e.g., eligibility cri-
teria, outcomes definitions).
Confidence in cumulative evidence
The strength of the body of evidence will be assessed
through the Grading of Recommendations, Assessment,
Development, and Evaluations (GRADE) certainty rat-
ings. Using GRADE guidelines [28, 29], the researchers
will examine the following domains for a decrease in
certainty: risk of bias, imprecision of true effects, incon-
sistency of effects, indirectness of outcomes, and publi-
cation bias.
Discussion
The purpose of this umbrella review is to elucidate
the associations between prenatal use of analgesic
drugs and children’s neurodevelopmental disorder
diagnoses through the synthesis of relevant published
research. Findings from this review will provide a
clearer direction for clinical decisions made during
pregnancy in relation to the use of analgesic drugs. A
small sample of papers will be selected to conduct at
the pilot as an initial stage of the umbrella review, in-
cluding search strategies, inclusion/exclusion criteria,
data extraction, and quality assessments. The results
of the pilot will be used to refine data extraction in
the full umbrella review or if necessary, modification
of the scope of the review before proceeding with the
full review.
Potential practical issues may present proposed search
terms producing irrelevant results, in which the team
will then redefine current search strategies. If key vari-
ables are missing from our data extraction plan, all
amendments to the protocol will be documented and re-
ported thoroughly. All amendments to the protocol will
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be documented in a separate summary sheet, which will
be submitted in the final umbrella review.
A potential limitation of this review could involve diffi-
culties in synthesizing information due to methodo-
logical differences of original studies leading to
heterogeneous results in the selected reviews. Another
limitation could arise from the emphasis of AMSTAR 2;
due to its original focus of being a tool for randomized
controlled clinical trials of interventions, several items in
the AMSTAR 2 are not entirely relevant to this umbrella
review, such as question 8 where the description of stud-
ies in adequate detail had to have “interventions” as an
option to fulfill the criteria of “Yes” (Additional File 2).
To mitigate this, the AMSTAR 2 will be modified to suit
the topic of our umbrella review.
However, this also offers an opportunity to discuss
these methodological differences and provide clear
suggestions for future research. Using synthesized in-
formation on analgesic drugs and their association
with neurodevelopmental outcomes, there are several
strengths of this proposed review. A strength of the
proposed review lies in the added value of synthesiz-
ing findings from previous reviews on the effects of
prenatal use of analgesic medications on children’s
long-term neurodevelopment. To our knowledge, no
such review has been conducted on this topic as of
yet. Findings could help refine clinical practices for
the prenatal period and increase the quality of avail-
able information which future decisions in healthcare
policy are based on.
Protocol amendments
Any amendments made to the protocol will be docu-
mented throughout the review process and will also be
discussed in the paper submitted for publication.
Dissemination plans
The umbrella review will be written up and submitted
for publication in a peer-reviewed journal. Findings will
be presented at relevant conferences. We will work with
the University of Edinburgh press and knowledge ex-
change offices on dissemination through press releases,
targeted toward a wide audience, including
policymakers.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13643-020-01465-9.
Additional file 1:. Data extraction form.
Additional file 2:. AMSTAR 2.
Additional file 3:. Draft search.
Additional file 4:. Figure S1. PRISMA Flow Diagram.
Additional file 5:. PRISMA-P 2015 Checklist.
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